Work

Trial in progress: Durvalumab and olaparib for the treatment of prostate cancer in men predicted to have a high neoantigen load.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps5099

Authors: Alexandra Sokolova, Roman Gulati, Heather H. Cheng, Tomasz M. Beer, Julie N Graff, Melanie Amador, Andrea Toulouse, Kamilah Taylor, Shawna Bailey, Steven Smith, Shaadi Tabatabaei, Ryan Sinit, Rachel Slottke, Jacqueline Vuky, Todd Yezefski, Petros Grivas, Evan Y. Yu, Michael Thomas Schweizer

Institutions: Oregon Health & Science University, OHSU Knight Cancer Institute, Fred Hutch Cancer Center, University of Washington, VA Portland Health Care System

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281703698

Cites:

Cited by:

Related to: 10